ライフサイエンスコーパス: HIFU

1 HIFU ablation was performed in one session with US guida

2 HIFU also increased the uptake of the antibody in surrou

3 HIFU combined with TACE is a safe and promising method w

4 HIFU has passed regulatory approval around the world for

5 HIFU is a non-invasive and highly effective standard tre

6 HIFU is a non-invasive approach that uses a precisely de

7 HIFU is often used for ablative therapies and must be ad

8 HIFU provides an excellent option to treat uterine fibro

9 HIFU treatment for localized PC can be considered as an

10 HIFU-induced bubbles provide an alternative means to des

11 h a diagnostic ultrasound machine during 180 HIFU exposures of five freshly excised, degassed bovine

12 were evaluated (SBRT, n = 40; TACE, n = 59; HIFU, n = 51).

13 A HIFU setup capable of controlling the excitation pressur

14 and photophobia in the right eye following a HIFU application to the superior right eyelid.

15 Compared with traditional ablative HIFU, nondestructive pulsed HIFU (pHIFU) is present in t

16 Across HIFU exposure amplitude ranges, passive acoustic mapping

17 Studies addressing HIFU in leiomyomas were identified from a search of the

18 MATERIAL/METHODS: Studies addressing HIFU in localized PC were identified in a search of inte

19 After HIFU, (68)Ga-RM2 and (68)Ga-PSMA11 PET/MRI both identifi

20 A11 PET/MRI in each patient before and after HIFU to assess the accuracy of target tumor localization

21 ient was found to have lung metastasis after HIFU and had an operation to remove the lesion.

22 ment was assessed at a minimum of 6 mo after HIFU with prostate biopsy (n = 13), as well as (68)Ga-PS

23 ive template biopsy and negative mpMRI after HIFU from an ongoing clinical trial (NCT02265159).

24 e potential to localize PCa recurrence after HIFU occult on mpMRI.

25 tment SUV(max) decreased significantly after HIFU for (68)Ga-PSMA11 (P = 0.001) and (68)Ga-RM2 (P = 0

26 ecific antigen decreased significantly after HIFU, by 66%.

27 All HIFU heating strategies combined with TSLs resulted in c

28 d with TACE (28.9% and 45.8%; P = 0.034) and HIFU (33.3% and 45.1%; P = 0.032).

29 ecent years, improvements in cryotherapy and HIFU have increased efficacy whereas decreasing complica

30 ble of simultaneous fluorescence mapping and HIFU ablation.

31 However, MB and HIFU are limited by the half-life of the contrast agent

32 e frequent after SBRT compared with TACE and HIFU (48.1% vs. 25% vs. 17.9%, respectively; P = 0.037).

33 tly higher after SBRT compared with TACE and HIFU (92.3%, 43.5%, and 33.3%, respectively; P = 0.02).

34 ll patients received chemotherapy, TACE, and HIFU ablation.

35 f whole-heart (n=6) preparations by applying HIFU at clinical doses (4-16 W).

36 l hyperecho technique as an ultrasound-based HIFU monitoring method, as both a detector of lesion occ

37 Before HIFU, (68)Ga-PSMA11 identified all target tumors, wherea

38 Before HIFU, the patients underwent prostate biopsy, multiparam

39 Conclusion: PSMA PET scans performed before HIFU identified 12% of patients who were unsuitable for

40 t of Gd(DTPA)(2-) released was controlled by HIFU stimulation times and power levels.

41 igen, cytokines and cell debris liberated by HIFU enhance response to innate immune agonists.

42 MSNs, and the release of cargo molecules by HIFU occurs without substantial temperature increase (~4

43 used to assess functional damage produced by HIFU.

44 U, the release of Gd(DTPA)(2-) stimulated by HIFU was pinpointed at the HIFU focal point in 3-D space

45 n bulk tissues in large animals and clinical HIFU system revealed correlation between therapeutic eff

46 on the same bulk tissues although different HIFU systems were used.

47 isplacement of 1 to 3 mm was observed during HIFU application due to acoustic radiation force along t

48 corresponding Doppler power maps after each HIFU pulse.

49 lease following short duration ( 20min each) HIFU treatments administered sequentially over an hour i

50 lease following short duration (~20min each) HIFU treatments administered sequentially over an hour i

51 Mice received either HIFU alone or were primed with the toll-like receptor 9

52 ironment, Ultrasound-High-Intensity Focused (HIFU), Ablation Techniques, Abdomen/GI, Genital/Reproduc

53 trasound, Ultrasound-High Intensity Focused (HIFU), Interventional-MSK, Interventional-Body, Oncology

54 tive changes in different patients following HIFU.

55 d at acute and chronic time points following HIFU application.

56 included all patients who were scheduled for HIFU between June 2017 and May 2022 and underwent a PSMA

57 nance imaging enables accurate targeting for HIFU as well as temperature monitoring during treatment.

58 -RM2 PET/MRI identified the target tumor for HIFU in 100% and 86% of cases, respectively, and accurat

59 acoustic pressure and high temperature from HIFU generated cavitation, causing macroscopic tissue da

60 Furthermore, HIFU upregulated multiple innate immune receptors and im

61 45 C), or (iii) ablative high intensity FUS (HIFU).

62 In conclusion, image-guided HIFU demonstrates deep energy penetration, safety and sp

63 Interventional nuclear image-guided HIFU is an attractive noninvasive option for the future.

64 e demonstrated the potential of image-guided HIFU to reduce adverse effects and increase the quality

65 his work a magnetic resonance imaging guided HIFU (MRgHIFU) controlled feedback system was developed

66 MR imaging-guided HIFU ablation of bone may result in progressive remodeli

67 maging 3 and 6 weeks after MR imaging-guided HIFU ablation were similar between proximal (low-energy)

68 itor bone remodeling after MR imaging-guided HIFU ablation.

69 ents who were treated with MR imaging-guided HIFU only.

70 idence of the potential of MR imaging-guided HIFU to be part of a routine strategy for the treatment

71 MR imaging-guided HIFU was used to create distal and proximal ablations in

72 clinical effectiveness of MR imaging-guided HIFU were considered primary outcomes; tumor control at

73 cal efficacy and safety of MR imaging-guided HIFU were demonstrated.

74 nd no contraindications to MR imaging-guided HIFU were enrolled between June 2010 and June 2013.

75 cruited patients underwent MR imaging-guided HIFU.

76 ss the immunomodulatory effects of MR-guided HIFU and its combination with the innate immune agonist

77 Magnetic resonance-guided HIFU triggered shape-recovery of a device made of polyur

78 achieved with 8 seconds of ultrasound-guided HIFU with millimeter resolution energy focus.

79 Early data suggest that US-guided HIFU ablation is an effective and safe procedure for tre

80 In HIFU, ultrasound energy from an extracorporeal source is

81 BRT, 45%, 54.9% in TACE, and 47.6%, 62.8% in HIFU; P < 0.001).

82 progressed, the delivery of Dox decreased in HIFU-treated tumors with ELTSLs, but this phenomenon was

83 The integration of imaging modalities into HIFU systems allows for precise temperature monitoring a

84 This review presents the latest HIFU applications, from investigational to clinically ap

85 hod exhibits a great potential for measuring HIFU field under high-pressure amplitude.

86 Both mechanical HIFU and thermal ablation induced a potent inflammatory

87 Most HIFU therapies are designed to use heating effects resul

88 ees C) was applied to the tumors using an MR-HIFU system.

89 and injected in tumor-bearing rats before MR-HIFU treatment.

90 ted outcome and patient management during MR-HIFU procedure.

91 We have demonstrated a workflow for MR-HIFU hyperthermia drug delivery that can be adapted to a

92 For the LTSL + MR-HIFU group, mild hyperthermia (40-41 degrees C) was appl

93 LTSL + MR-HIFU resulted in significantly higher tumor doxorubicin

94 In contrast, LTSL + MR-HIFU treatment suggested an improved distribution with d

95 ) free doxorubicin, 2) LTSL and 3) LTSL + MR-HIFU.

96 guided High-Intensity Focused Ultrasound (MR-HIFU) is a noninvasive technique for ablation therapy fo

97 guided high intensity focused ultrasound (MR-HIFU) platform to investigate in vivo image-guided drug

98 guided high-intensity focused ultrasound (MR-HIFU) was used as a noninvasive heating device with prec

99 2)) based thermosensitive liposomes using MR-HIFU mediated hyperthermia in a swine model.

100 on, hyperthermia followed by ablation, or no HIFU.

101 In spite of the benefits of HIFU, a number of limitations have been reported, which

102 In the characterization of HIFU fields, the effect of nonlinear propagation is cons

103 o evaluate thermal and nonthermal effects of HIFU in cardiac ablation.

104 The safety and efficacy of HIFU integration with current cancer treatment strategie

105 al mechanisms responsible for the failure of HIFU ablation in cardiac tissues.

106 o review HIFU to explain the fundamentals of HIFU, evaluate the evidence concerning the role of HIFU

107 h adequate mpMRI and PSMA PET within 6 mo of HIFU.

108 Results show the potential of HIFU-mediated hyperthermia for enhanced delivery of poly

109 the release profile by varying the power of HIFU, the duration of exposure to HIFU, or both.

110 vely measuring the peak positive pressure of HIFU fields.

111 xposed to hyperthermia and high pressures of HIFU (8.2 MPa peak-to-peak free-field at 1 MHz) relative

112 ine fibroid therapy, to evaluate the role of HIFU in the therapy of leiomyomas as well as to review t

113 evaluate the evidence concerning the role of HIFU in the treatment of prostate cancer (PC), review th

114 The most studied therapeutic uses of HIFU involve thermal tissue ablation, demonstrating both

115 Clinical research on HIFU therapy for leiomyomas began in the 1990s, and the

116 Clinical research on HIFU therapy for localized PC began in the 1990s, and th

117 In current gynecologic oncology, HIFU is used clinically in the treatment of leiomyomas.

118 In current urological oncology, HIFU is used clinically in the treatment of PC.

119 When exposed to direct heating or HIFU, the PCM will melt and escape from the interiors of

120 ive cohort of patients who underwent TACE or HIFU from 2010.

121 PC), review the technologies used to perform HIFU and the published clinical literature regarding the

122 t a PSMA PET scan within 6 mo before planned HIFU for initial therapy of low-risk or intermediate-ris

123 Patients with lower pre-HIFU PSA level and favourable pathologic Gleason score s

124 Results: Pre-HIFU biopsy revealed 18 cancers, of which 14 were clinic

125 es based on a rabbit model and a preclinical HIFU system.

126 Current primary HIFU indications are pain palliation, complete ablation

127 f low-risk or intermediate-risk PCa (primary HIFU) or local recurrence after radiotherapy (salvage HI

128 Tumors in the control group, pulsed HIFU and control group, and 1.0 mg/kg of bortezomib alon

129 However, pulsed HIFU and 1.0 mg/kg bortezomib increased the time to end

130 itional ablative HIFU, nondestructive pulsed HIFU (pHIFU) is present in the majority of novel applica

131 each group, half of the mice received pulsed HIFU exposure to their tumors immediately prior to each

132 Treatment of tumors with pulsed HIFU lowered the threshold level for efficacy of bortezo

133 The ability of pulsed-HIFU (1 M Hz, spatial averaged temporal peak intensity=2

134 netration and therapeutic efficacy of pulsed-HIFU exposures combined with (90)Y labeled B3 mAb in an

135 beled with cytotoxic radioisotopes or pulsed-HIFU exposure in addition to a combined therapy of (90)Y

136 This study demonstrates that pulsed-HIFU significantly enhances the delivery of (111)In-MX-B

137 The pulsed-HIFU exposures did not affect the vascular parameters in

138 ed high intensity focused ultrasound (pulsed-HIFU) has previously been shown to increase the accumula

139 al, following various treatments with pulsed-HIFU and/or (90)Y-B3.

140 Pretreatment with pulsed-HIFU significantly improved (p-value<0.05) survival over

141 ved (p-value<0.05) when combined with pulsed-HIFU, only in the tumor periphery.

142 o the solid tumors when combined with pulsed-HIFU.

143 A tumor on one flank was treated with pulsed-HIFU; the other tumor was used as an untreated control.

144 f other treatment regimens, such as repeated HIFU exposures for greater delivery enhancement of antib

145 This study intended to review HIFU in uterine fibroid therapy, to evaluate the role of

146 This study intended to review HIFU to explain the fundamentals of HIFU, evaluate the e

147 local recurrence after radiotherapy (salvage HIFU).

148 y suggest that short duration and sequential HIFU treatment could have significant benefits and that

149 nd lens opacity formation following a single HIFU superior eyelid application.

150 The present strategy, HIFU-TiO2-SCX-LC-MS/MS, is the fastest analytical method

151 t, and uniaxial compression/tension testing, HIFU irradiation provides spatiotemporal control of the

152 A second reaction is the demonstration that HIFU irradiation successfully triggers a luminescent dio

153 adapted to a clinical setting, showing that HIFU-hyperthermia is a suitable method for local drug re

154 The HIFU effect on enhancing tumor uptake was greater at ear

155 The HIFU effect on enhancing tumor uptake was substantiated

156 The HIFU exposure shortened the peak tumor uptake time (24 v

157 Within 10 min after the HIFU exposure, the mice received intravenous (111)In-MX-

158 2-) stimulated by HIFU was pinpointed at the HIFU focal point in 3-D space in a tissue-mimicking gel

159 ology and safety will undoubtedly expand the HIFU role in this indication as more of patient series a

160 For the HIFU group, mild hyperthermia (40-42 degrees C) was comp

161 Safety protocols of the HIFU intensity threshold for thermal lesions in the eye

162 on tumor, and 3) determine the impact of the HIFU/nanobubble combination on intratumoral drug distrib

163 on tumor, and 3) determine the impact of the HIFU/nanobubble combination on intratumoral drug distrib

164 We found that the HIFU exposure induced a mild regional neuroinflammation

165 al cone adaptor has been designed to use the HIFU beam at a pre-defined post-focal distance.

166 sibility of a recently developed approach to HIFU-induced ultrasound-guided tissue fractionation in a

167 e power of HIFU, the duration of exposure to HIFU, or both.

168 nal changes on the hemisphere ipsilateral to HIFU exposure are of greater magnitude than the contrala

169 ever, better methods to evaluate response to HIFU ablation are an unmet need.

170 matory factors will be secreted secondary to HIFU activation, which is in the vicinity of the enginee

171 ted using high intensity focused ultrasound (HIFU) and microbubbles (MBs) can improve tumor drug deli

172 High-intensity focused ultrasound (HIFU) applies high-intensity focused ultrasound energy t

173 by using high-intensity focused ultrasound (HIFU) as a remote energy source to drive the spatially a

174 ng pulsed high-intensity focused ultrasound (HIFU) as an adjunctive pretreatment to bortezomib, a pro

175 ovided by high-intensity focused ultrasound (HIFU) combined with an inverse strategy based on TiO2 se

176 veness of high-intensity focused ultrasound (HIFU) combined with transarterial chemoembolization (TAC

177 if pulsed high-intensity focused ultrasound (HIFU) exposures could enhance tumor uptake of (111)In-MX

178 ge-guided high-intensity focused ultrasound (HIFU) has been increasingly used in medicine over the pa

179 High intensity focused ultrasound (HIFU) has been introduced for treatment of cardiac arrhy

180 ge-guided high-intensity focused ultrasound (HIFU) heating is tested.

181 High-intensity focused ultrasound (HIFU) is a cosmetic procedure that aims to tone the skin

182 High-intensity focused ultrasound (HIFU) is a highly precise medical procedure used locally

183 High-intensity focused ultrasound (HIFU) is a promising new modality for the treatment of l

184 ng-guided high-intensity focused ultrasound (HIFU) is a safe, effective, and durable treatment option

185 High Intensity Focused Ultrasound (HIFU) is an emerging noninvasive, nonionizing physical e

186 High-intensity focused ultrasound (HIFU) is an increasingly used, locally ablative therapy

187 PC) using high-intensity focused ultrasound (HIFU) is gaining in popularity as it is noninvasive and

188 (BH) is a High Intensity Focused Ultrasound (HIFU) method for precise mechanical disintegration of ta

189 High intensity focused ultrasound (HIFU) rapidly and non-invasively destroys tumor tissue.

190 High-intensity focused ultrasound (HIFU) surgery is a noninvasive technique performed under

191 al use of high intensity focused ultrasound (HIFU) therapy for noninvasive tissue ablation has been r

192 ting of a High Intensity Focused Ultrasound (HIFU) transducer with centre frequency 3.57 MHz, a power

193 ting with high-intensity focused ultrasound (HIFU) under MRI guidance to remotely permeabilize BBB.

194 fector by high-intensity focused ultrasound (HIFU).

195 osions or high-intensity focused ultrasound (HIFU).

196 posure to high intensity focused ultrasound (HIFU).

197 TACE) and high-intensity focused ultrasound (HIFU).

198 -invasive high intensity focused ultrasound (HIFU).

199 Under HIFU irradiation evidence of the mechanochemical transdu

200 luded in the cohort, 3 (12%) did not undergo HIFU after the PSMA PET scan because of PCa upstaging.

201 Uterine fibroid treatment using HIFU was effective and safe in treating symptomatic uter

202 Adverse events associated with HIFU were evaluated.

203 urvival (FFS) rates in patients treated with HIFU after undergoing prostate-specific membrane antigen